

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Relationship between right-to-left shunt and migraine in patients with epilepsy

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024144
Article Type:	Research
Date Submitted by the Author:	12-May-2018
Complete List of Authors:	Zhang, Lin Zhu, Xi Qiu, XIangmiao Li, Yajiao Chen, Yucheng Wang, Hui He, Shixu Lai, Wanlin Peng, Anjiao Ning, Mingming Chen, Lei; West China Hospital, Sichuan University, Chengdu, Sichuan, China,
Keywords:	Epilepsy < NEUROLOGY, Migraine < NEUROLOGY, Right-to-left shunt

SCHOLARONE™
Manuscripts

Relationship between right-to-left shunt and migraine in patients with epilepsy

Lin Zhang,¹ Xi Zhu,¹ Xiangmiao Qiu,¹ Yajiao Li,² Yucheng Chen,² Hui Wang,² Shixu He,¹ Wanlin Lai,¹ Anjiao Peng,¹ Mingming Ning,³ Lei Chen,¹

¹Department of Neurology, West China Hospital, Sichuan University, Chengdu, China

²Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China

³Department of Neurology, Cardio-Neurology Clinic, Massachusetts General Hospital, Harvard Medical School, Boston, USA

Email for each author: Lin Zhang (zhanglinneur@163.com), Xi Zhu (zhu61900@163.com), Xiangmiao Qiu (qiuxmiao@126.com), Yajiao Li (liyajiao800@163.com), Yucheng Chen (chenyucheng2003@126.com), Hui Wang (dashu1985723@163.com), Shixu He (274464077@qq.com), Wanlin Lai (laiwl93@163.com), Anjiao Peng (peng_neurology@163.com), Mingming Ning (Ning@hms.harvard.edu), Lei Chen (leilei_25@126.com)

Key words: right-to-left shunt; epilepsy; migraine

Number of words (main text): 2189

ABSTRACT

Objectives To investigate the relationship between right-to-left shunts (RLS) and migraine to account for the unexplained high prevalence of migraine in patients with epilepsy (PWE).

Design This is a cross-sectional study. The diagnosis and interview process of patients with migraine was based on the International Classification of Headache disorders in PWE. Participants underwent transthoracic echocardiography (TTE) with contrast medium to identify RLS. The highest number of microbubbles were recorded in the left atrium before the complete microbubble outflow of the right atrium. Moderate to large RLS was defined as the presence of 10 or more microbubbles.

Setting Single-center, 2015-2017.

Participants Patients with epilepsy.

Primary and secondary outcome measures Main outcome measures were the prevalence of migraine, RLS prevalence in PWE with and without migraine, and the prevalence of migraine in different degree of shunting.

Results Three hundred and thirty-nine participants with epilepsy who completed TTE were included in the analysis. The overall prevalence of migraine was 23.0%. Almost one-third of migraineurs have mild RLS and one-fifth of migraineurs have moderate to large RLS. Patients with mild RLS did not have a higher prevalence of migraine than those without RLS (26.3% vs 18.1%, $p = 0.102$), however, a higher prevalence of migraine was found in patients with moderate to large RLS (39.0% vs 18.1%, odds ratio = 2.90, 95% confidence interval = 1.41 to 5.98, $p = 0.003$). PWE with and without migraine had similar prevalence of mild RLS, however, patients with migraine had more moderate to large RLS (20.5% vs 9.6%, $p=0.002$). RLS, older age and female were factors predicting migraine prevalence.

1
2
3 **Conclusions** Almost one-fifth of migraineurs were correlated with moderate-to-large
4 RLS which could be an underlying cause of migraine in epilepsy. PWE with migraine
5 should be screened for RLS.
6
7
8
9

10
11 **Strengths and limitations of this study**
12

- 13 ▶ Cohort study with data from a large number of patients with epilepsy.
14
15 ▶ We firstly studied the relationship between the degree of shunts and migraine in
16 patients with epilepsy.
17
18 ▶ Transthoracic echocardiography with contrast medium was used as a tool to detect
19 right-to-left shunt but not transoesophageal echocardiography.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Comorbidity of migraine is common in patients with epilepsy (PWE). The lifetime occurrence of migraine was up to 33.6% of PWE, representing an overall 52% increase relative to people without epilepsy.^{1 2} Comorbid migraine may have an unfavourable effect on the prognosis of epilepsy in children and adults.^{3 4} Evidence of genetics and animal experiments suggested similar pathophysiological mechanisms between migraine and familial epilepsy, such as genetic variants and abnormal neuronal excitability.⁵⁻⁹ Despite these findings, the mechanisms underlying migraine in PWE are still controversial.

In the past 2 decades, right-to-left shunt (RLS), usually due to patent foramen ovale (PFO) and pulmonary arteriovenous shunts, have been found to be associated with migraine. Three-fold higher migraine with aura was observed in patients with PFO compared to people without PFO.¹⁰ There are clinical trials showing that patients with PFO closure had a significantly greater reduction in headache days although responder rate defined as 50% reduction in migraine attacks is not different.^{11 12} In addition, the meta-analyses showed a complete resolution of migraine post-PFO closure occurred in 54% of migraine-with-aura cases and in 39% of migraine-without-aura cases.^{13 14} Therefore, PFO may be a fundamental cause in migraine. One of the possible mechanisms between the 2 conditions is that vasoactive chemicals triggering migraine bypass the pulmonary filter.⁵ In addition, the presence of microemboli in patients with PFO is higher than in patients without PFO.¹⁵ Animal experiments showed that microemboli can trigger the aura phenomenon by inducing cortical spreading depression (CSD).⁷

Similarly, PFO may also induced migraine by vasoactive chemicals and microemboli in PWE. Therefore, our main aim was to investigate the relationship

1
2
3 between RLS and migraine to account for the unexplained high prevalence of
4 migraine in epilepsy. We also investigated other migraine predictive factors, for
5 example, sex, age, familial epilepsy, duration of epilepsy and antiepileptic drugs
6 (AEDs).
7
8
9
10

11 12 13 **METHODS**

14 **Study design and patients**

15
16 This is a cross-sectional study. Study populations were consecutively recruited
17 between June 2015 and December 2017 from the Department of Neurology, West
18 China Hospital, Sichuan University, China. Participants or legal guardians signed
19 informed consent. Exclusion criteria were as follows: (1) age <3 years; (2) inaccurate
20 communication because of language problems; (3) patients with one seizure (because
21 high recurrence risk factors are controversial) and provoked seizures; (4)
22 undetermined diagnosis of epilepsy; (5) clinical history of epilepsy including onset
23 age of seizure, AEDs, familial history of epilepsy, seizure frequency in the last year
24 and types of seizure were not recorded; (6) history of heart disease except RLS; (7)
25 RLS confirmed by transthoracic echocardiography (TTE) at another hospital (because
26 there may be differences between sonographers); and (8) informed consent not signed.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 **Definitions and collection of data**

45
46 A definitive diagnosis and classification of epilepsy met the criteria proposed by the
47 International League Against Epilepsy (ILAE) based on clinical history, seizure
48 semiology, electroencephalography (EEG) and magnetic resonance imaging (MRI)
49 findings.¹⁶ For each patient, age, symptoms of seizure, onset age of seizure, AEDs,
50 education status, seizure onset with visual symptoms, history of febrile seizure,
51
52
53
54
55
56
57
58
59
60

1
2
3 seizure frequency in the last year, familial history of epilepsy and types of seizure
4 (focal onset, focal to bilateral tonic-clonic seizures, or generalized onset) were
5 recorded.
6
7

8
9 The diagnosis and interview process for patients with migraine were based on the
10 International Classification of Headache disorders (ICHD-3 beta).¹⁷ The numbers of
11 migraine attacks, estimated duration of migraine, location, quality, intensity (visual
12 analogue scale, 0-10) and aura were recorded. Patients would not be classified as
13 having migraine if only postictal and ictal migrainous headache occurred because
14 ICHD-3 beta does not have related criteria. Every patient was diagnosed by 2
15 neurologists separately. If the diagnosis of epilepsy and migraine was inconsistent, a
16 third senior neurologist was asked to discuss the case further.
17
18
19
20
21
22
23
24
25

26 For children, their parents (or the children themselves if they were old enough)
27 were asked to give specific information about epilepsy and migraine. Medical records
28 and seizure diaries during the last 12 months were reviewed to obtain information
29 regarding the history of epilepsy and migraine, EEG and MRI.
30
31
32
33
34
35
36
37

38 **Transthoracic Echocardiography**

39 Participants underwent transthoracic echocardiography (TTE) with contrast medium
40 and 1-5 MHz or 3-8MHz multiplane transducers in Philips IE33 to identify RLS; this
41 was performed by 2 experienced sonographers who also analysed the videotapes
42 together. Patients with other cardiac diseases (such as valvular heart diseases and
43 cardiomyopathy) found by TTE were excluded. A microbubble bolus of agitated
44 solution of 9 mL saline and 1 mL air was injected into one side of the patients'
45 antecubital veins for increased sensitivity.^{18 19} Patients were assessed for an RLS at
46 rest and during Valsalva's manoeuvre and coughing. The highest number of
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 microbubbles were recorded in the left atrium before the complete microbubble
4
5 outflow of the right atrium. If 3 or more microbubbles appeared, an RLS was
6
7 diagnosed. The degree of shunting was defined as grade 0 if 0 to 2 microbubbles
8
9 occurred, grade 1 (mild) if 3 to 9 microbubbles occurred, grade 2 (moderate) if 10 to
10
11 30 microbubbles occurred and grade 3 (large) if more than 30 microbubbles
12
13 occurred.²⁰
14
15

16 17 18 **Data analysis**

19
20 Data were collected using the same standard forms in Microsoft Excel (version 2013).
21
22 Continuous variables were compared by ANOVA. Categorical variables were
23
24 compared using the χ^2 test or Fisher's exact test, as appropriate. Bonferroni correction
25
26 was used if necessary. Logistic regression analyses were used to determine whether
27
28 some variables were migraine-predicting factors. For all statistical tests, $p < 0.05$ was
29
30 determined to be statistically significant. Statistics were performed using the SPSS
31
32 statistical package (version 21.0).
33
34
35
36
37

38 **Patient and public involvement**

39
40 The development of the research question and outcome measures were informed by
41
42 published literature on PFO and migraine. Patients' priorities, experience and
43
44 preferences were not involved in designing the study. Patients who agreed to enrol to
45
46 the study received TTE. The recruitment process was mentioned in the Study design
47
48 and patients section. Two authors (Lin Zhang and Xi Zhu) disseminated the results to
49
50 the study participants by interviews.
51
52
53

54 **RESULTS**

1
2
3 We carefully interviewed 532 patients with seizure (s) or (and) their parents. One
4
5 hundred and sixty-one patients were excluded. The reasons for exclusion were
6
7 showed in figure 1. Three hundred and thirty-nine participants with epilepsy who
8
9 completed the interview process of migraine and TTE were included in the analysis.
10
11 The details of migraine features according to the ICHD-3 beta criteria showed in the
12
13 supplementary. The overall prevalence of migraine was 23.0% (table 1). A greater
14
15 percentage of females had migraines than males (28.8% vs 17.2%, $p = 0.022$).
16
17 Patients > 16 years seemed to have higher prevalence of migraine than those ≤ 16
18
19 years of age (25.7% vs 11.0%, $p = 0.039$). If the duration of epilepsy was > 10 years,
20
21 patients were more likely to have migraines (34.6% vs 17.9%, $p = 0.001$). Patients
22
23 with polytherapy may have more migraines (28.0% vs 19.0%, $p = 0.052$). Patients
24
25 with first-degree and second-degree relatives with epilepsy may have not more
26
27 migraines.
28
29
30

31 Almost one-third of migraineurs have mild RLS and one-fifth of migraineurs have
32
33 moderate to large RLS (table 1 and table 2). Patients with mild RLS did not have a
34
35 higher prevalence of migraine than those without RLS (26.3% vs 18.1%, odds ratio =
36
37 1.61, 95% confidence interval = 0.91 to 2.87, $p = 0.102$). In our cohort, 33.3% (26 of
38
39 78) of PWE with migraine and 28.0% (73 of 261) of PWE without migraine had mild
40
41 RLS ($p = 0.361$).
42
43

44 Patients with moderate to large RLS had a higher prevalence of migraine than those
45
46 without RLS (39.0% vs 18.1%, odds ratio = 2.90, 95% confidence interval = 1.41 to
47
48 5.98, $p = 0.003$, table 1 and table 2). Twenty-one percent (16 of 78) of PWE with
49
50 migraine had moderate to large RLS; whereas only 10% (25 of 261) of PWE without
51
52 migraine had moderate to large RLS (odds ratio = 2.44, 95% confidence interval =
53
54 1.23 to 4.84, $p=0.002$). After controlling the potential confounders, there are
55
56
57
58
59
60

1
2
3 significant differences of migraine prevalence between the groups with RLS grade 2-3
4 versus the group with RLS grade 0 (table 2). Therefore, moderate to large RLS but not
5 mild RLS was associated with migraine in PWE.
6
7

8
9 We used a logistic regression analysis to identify the possible factors predicting
10 migraine prevalence, such as sex, onset age, duration of epilepsy, current age, RLS
11 and AEDs (table 3). RLS, older age and female were factors predicting migraine
12 prevalence. Although patients with duration of epilepsy >10 years seemed to have
13 higher migraine prevalence (table 1), the logistic regression analysis showed longer
14 duration of epilepsy may be not a predictive factor.
15
16
17
18
19
20
21

22 PFO closure were performed in 7 patients. Four patients were followed for 6 month.
23 We found that PFO closure full control migraine in 2 of 4 cases. Before PFO closure,
24 the two patients have more than 11 migraine attacks in the last year. More interesting,
25 the frequency of seizures in 3 patients with migraine after PFO closure decreased
26 significantly.
27
28
29
30
31
32
33
34

35 **DISCUSSION**

36 This is the first study to evaluate the relationship between migraine and RLS in a
37 large number of PWE. Our main findings were as follows: 1) Almost one-third of
38 migraineurs have mild RLS and one-fifth of migraineurs have moderate to large RLS;
39 2) mild RLS did not have a higher prevalence of migraine than those without RLS; 3)
40 moderate to large RLS was associated with migraine in PWE and 4) RLS, older age
41 and female were factors predicting migraine prevalence in PWE.
42
43
44
45
46
47
48
49

50 The pathophysiological mechanisms of migraine in PWE were usually considered
51 to be common genetic variants and abnormal neuronal excitability.⁵⁻⁹ Our major
52 hypothesis was that RLS may be one of pathophysiological mechanisms of migraine
53
54
55
56
57
58
59
60

1
2
3 in PWE. The results showed that mild RLS were not associated with migraine in PWE.
4
5 Almost one-fifth of migraine were correlated with moderate-to-large RLS which
6
7 could be an underlying cause of migraine in epilepsy. The mechanisms of the
8
9 relationship between moderate to large RLS and migraine remains speculative. A
10
11 previous study showed larger RLS tend to trigger migraine attacks because of the
12
13 increased extent of the shunt.²¹ Larger shunts allow harmful circulatory factors, such
14
15 as vasoactive substances and microemboli which are eliminated by lung, to bypass the
16
17 pulmonary filter and travel directly from the venous to the cerebral artery. PFO and
18
19 higher rates of Doppler-detected cerebral microemboli have been reported to be
20
21 associated.²² In an animal experiment, air microemboli are able to trigger cortical
22
23 spreading depression (CSD) and migraine aura often with transient microvascular
24
25 occlusion which is insufficient to cause a permanent ischemic lesion.⁷ In human,
26
27 diagnostic microbubble injection also induced attacks of migraine with aura.²³
28
29 Therefore, microemboli may be a key role linking CSD, migraine and moderate to
30
31 large RLS.
32
33

34
35 More interesting, CSD increases neuronal excitability and triggers ictal activity
36
37 in neuronal tissues with partial impairment of inhibitory.⁹ CSD also triggers migraine
38
39 headache by activating neuronal Panx1 channels which contributes to neuronal
40
41 hyperactivity in seizures.^{24 25} These may explain why migraine may have an
42
43 unfavourable effect on the prognosis of epilepsy.^{3 4} Therefore, moderate to large RLS
44
45 may be not only an underlying cause of migraine but also an adverse prognostic
46
47 factors in PWE. Whether moderate to large RLS is an adverse prognostic factors in
48
49 epilepsy should be also investigated.
50
51

52
53 We also investigated other migraine-predicting factors. Age showed effect on the
54
55 migraine prevalence and logistic regression analysis also showed that age was a
56
57
58
59
60

1
2
3 predicting factor of migraine. There are some possible explanations for this finding.
4
5 Previous studies found that PFO length and diameter increased with age which
6
7 implied the shunts also increased with age.²⁶ Larger shunts are more likely to trigger
8
9 migraine attacks.²¹ In addition, more cases of migraine would be diagnosed if
10
11 migraine occurred repeatedly as the duration of epilepsy became longer. Our results
12
13 also support the hypothesis that age affected migraine prevalence.
14

15
16 The effect of PFO closure for migraine treatment still remain controversial, but a
17
18 number of researches have proved to be effective, in particular in migraine with aura.
19
20 ^{13 14} In our cohort, we also found PFO closure full control migraine in 2 of 4 cases.
21
22 More interesting, the frequency of seizures in 3 patients with migraine after PFO
23
24 closure decreased significantly. Although the effect of PFO closure in these cases
25
26 needed to be explained with caution, it is worth investigating whether PFO closure
27
28 improved migraine attacks and seizure outcomes in future.
29

30
31 This study has some limitations. First, transoesophageal echocardiography (TEE) is
32
33 a gold standard diagnosis tool with a sensitivity and specificity of 80% to 100% for
34
35 detection of an RLS.^{18 19} The contrast TTE used by us has a lower sensitivity than
36
37 TEE.¹⁸ However, harmonic imaging improves sensitivity for the detection of RLS,
38
39 ranging from 66% to 100%.^{18 19 27 28} In addition, TTE is not inferior to TEE in the
40
41 assessment of large shunts because TEE may miss large shunts detected by TTE.²⁸ In
42
43 our study, moderate to large RLS are more likely to be associated with migraine,
44
45 therefore, TTE may not be an inferior choice to TEE. Second, the population may be
46
47 biased because a few patients did not complete TTE. However, there were no
48
49 differences in demographic characteristics between patients who did or did not refuse
50
51 TTE and the conclusions of our study should not be affected. Third, only Chinese
52
53 were recruited, and this limits generalizability of results.
54
55
56
57
58
59
60

CONCLUSIONS

Moderate to large RLS but not mild RLS was associated with migraine. Based on these results, PWE with migraine should be screened for RLS. Whether moderate to large RLS is an adverse prognostic factors in epilepsy should be also investigated.

Acknowledgements No patients advisers involved in the study. We thank Dr. Qi Si for her help.

Contributors Lei Chen and Mingming Ning conceived and designed the work. Lin Zhang and Xi Zhu were involved in data collection, data analysis and interpretation. Lin Zhang drafted the manuscript. Lei Chen involved in critical revision of the article and final approval of the version to be published. Xiangmiao Qiu, Xiangmiao Qiu, Shixu He, Anjiao Peng, Wanlin Lai, Yajiao Li, Yucheng Chen, and Hui Wang were involved in the data collection and final approval of the version to be published. All authors have agreed to be accountable for all aspects of the work.

Funding Funding for this study was provided by China Association Against Epilepsy (No.2016005).

Competing interests None declared.

Patient consent Obtained.

Ethics approval The protocol was approved by the Ethics Committee of the West

1
2
3 China Hospital of Sichuan University.
4
5
6

7 **Data sharing statement** No additional data available.
8
9

10
11 **REFERENCES**
12

- 13
14 1. Keezer MR, Bauer PR, Ferrari MD, et al. The comorbid relationship between
15 migraine and epilepsy: a systematic review and meta-analysis. *Eur J Neurol*
16 2015;22:1038-47.
17
18 2. Le H, Tfelt-Hansen P, Russell MB, et al. Co-morbidity of migraine with somatic
19 disease in a large population-based study. *Cephalalgia* 2011;31:43-64.
20
21 3. Dragoumi P, Tzetzzi O, Vargiami E, et al. Clinical course and seizure outcome of
22 idiopathic childhood epilepsy: determinants of early and long-term prognosis. *BMC*
23 *Neurol* 2013;13:206.
24
25 4. Velioglu SK, Boz C, Ozmenoglu M. The impact of migraine on epilepsy: a
26 prospective prognosis study. *Cephalalgia* 2005;25:528-35.
27
28 5. Finocchi C, Del Sette M. Migraine with aura and patent foramen ovale: myth or
29 reality? *Neurol Sci* 2015;36 Suppl 1:61-6.
30
31 6. Ludvigsson P, Hesdorffer D, Olafsson E, et al. Migraine with aura is a risk factor
32 for unprovoked seizures in children. *Ann Neurol* 2006;59:210-3.
33
34 7. Nozari A, Dilekoz E, Sukhotinsky I, et al. Microemboli may link spreading
35 depression, migraine aura, and patent foramen ovale. *Ann Neurol* 2010;67:221-9.
36
37 8. Winawer MR, Connors R. Evidence for a shared genetic susceptibility to migraine
38 and epilepsy. *Epilepsia* 2013;54:288-95.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9. Eickhoff M, Kovac S, Shahabi P, et al. Spreading depression triggers ictiform activity in partially disinhibited neuronal tissues. *Exp Neurol* 2014;253:1-15.
10. Takagi H, Umemoto T. A meta-analysis of case-control studies of the association of migraine and patent foramen ovale. *J Cardiol* 2016;67:493-503.
11. Xing YQ, Guo YZ, Gao YS, et al. Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine (EASTFORM) Trial. *Sci Rep* 2016;6:39081.
12. Tobis JM, Charles A, Silberstein SD, et al. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial. *J Am Coll Cardiol* 2017;70:2766-74.
13. Kanwar SM, Noheria A, DeSimone CV, et al. Coincidental Impact of Transcatheter Patent Foramen Ovale Closure on Migraine with and without Aura - A Comprehensive Meta-Analysis. *Clin Trials Regul Sci Cardiol* 2016;15:7-13.
14. Shi YJ, Lv J, Han XT, et al. Migraine and percutaneous patent foramen ovale closure: a systematic review and meta-analysis. *BMC Cardiovasc Disord* 2017;17:203.
15. Shariat A, Yaghoubi E, Nemati R, et al. Microembolic signals in patients with cryptogenic stroke with or without patent foramen ovale. *J Stroke Cerebrovasc Dis* 2012;21:662-6.
16. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia* 2017;58:522-30.
17. Ettl DA. *The International Classification of Headache Disorders, 3rd edition*

- (beta version). *Cephalalgia* 2013;33:629-808.
18. Cotter PE, Martin PJ, Belham M. Improved sensitivity of transthoracic contrast echocardiography in the detection of right-to-left shunts. *J Am Soc Echocardiogr* 2010;23:578; author reply 78-9.
19. Ha JW, Shin MS, Kang S, et al. Enhanced detection of right-to-left shunt through patent foramen ovale by transthoracic contrast echocardiography using harmonic imaging. *Am J Cardiol* 2001;87:669-71, a11.
20. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. *N Engl J Med* 2001;345:1740-6.
21. Tembl J, Lago A, Sevilla T, et al. Migraine, patent foramen ovale and migraine triggers. *J Headache Pain* 2007;8:7-12.
22. Rodriguez RA, Sinclair B, Weatherdon D, et al. Patent foramen ovale and brain microembolization during scoliosis surgery in adolescents. *Spine (Phila Pa 1976)* 2001;26:1719-21.
23. Dinia L, Roccatagliata L, Bonzano L, et al. Diffusion MRI during migraine with aura attack associated with diagnostic microbubbles injection in subjects with large PFO. *Headache* 2007;47:1455-6.
24. Karatas H, Erdener SE, Gursoy-Ozdemir Y, et al. Spreading depression triggers headache by activating neuronal Panx1 channels. *Science* 2013;339:1092-5.
25. Santiago MF, Veliskova J, Patel NK, et al. Targeting pannexin1 improves seizure outcome. *PLoS One* 2011;6:e25178.

- 1
2
3
4 26. McKenzie JA, Edwards WD, Hagler DJ. Anatomy of the patent foramen ovale for
5
6 the interventionalist. *Catheter Cardiovasc Interv* 2009;73:821-6.
7
8
9 27. Clarke NR, Timperley J, Kelion AD, et al. Transthoracic echocardiography using
10
11 second harmonic imaging with Valsalva manoeuvre for the detection of right to
12
13 left shunts. *Eur J Echocardiogr* 2004;5:176-81.
14
15
16 28. Daniels C, Weytjens C, Cosyns B, et al. Second harmonic transthoracic
17
18 echocardiography: the new reference screening method for the detection of patent
19
20 foramen ovale. *Eur J Echocardiogr* 2004;5:449-52.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Migraine prevalence in different groups

Characteristics	Sample	Migraine (%)	P
Male	169	29 (17.2)	0.022
Female	170	49 (28.8)	
Current age, years			0.039
≤16	82	12 (11.0)	
>16	257	66 (25.7)	
Duration of epilepsy, years			0.001
≤10	235	42 (17.9)	
>10	104	36 (34.6)	
Onset age, years			
≤16	183	39 (21.3)	0.421
>16	156	39 (25.0)	
Seizures onset with visual symptoms ^a	21	5 (23.8)	1.000 ^b
	293	69 (23.5)	
History of febrile seizures ^a	39	9 (23.1)	0.865
	259	63 (24.3)	
AEDs < or = 1	189	36 (19.0)	0.052
AEDs > or = 2	150	42 (28.0)	
Seizure types			0.319
Focal onset seizure	68	10 (14.7)	
Generalized onset seizure and	227	58 (25.6)	
FBTCS			
Undetermined	44	10 (22.7)	
Familial epilepsy	11	5 (45.5)	0.135 ^b

1				
2				
3	First-degree relatives	9	4 (44.4)	
4				
5	Second-degree relatives	2	1 (50.0)	
6				
7	No familial epilepsy	328	73 (22.3)	
8				
9	RLS grade 1	99	26 (26.3)	0.102
10				
11	RLS grade 2-3	41	16 (39.0)	0.003
12				
13	RLS grade 1-3	140	42 (29.6)	0.010
14				
15	RLS grade 0	199	36 (18.1)	
16				
17				

^a Cases with uncertain history were excluded.

^b Fisher's exact test

AEDs, antiepileptic drugs; FBTCS, focal to bilateral tonic-clonic seizures;

RLS, right-to-left shunt.

Table 2 High prevalence of migraine in patients with moderate to large RLS

Characteristics	Right-to-left shunting			P
	Grade 2-3 (41)	Grade 1 (99)	Grade 0 (199)	
Male	17	52	100	0.413
Age, years	26.9 ± 11.7	27.6 ± 13.7	26.4 ± 13.2	0.769
Onset age, years	19.3 ± 11.2	17.9 ± 12.4	17.8 ± 12.3	0.779
Duration, years	8.1 ± 8.9	9.7 ± 9.6	8.7 ± 9.1	0.580
Familial epilepsy	2	2	7	0.648
Education, years				0.772
0-6	13	24	52	0.645
7-12	20	47	104	
≥13	8	28	43	
Seizure types				0.085
Focal onset	7	22	39	
Generalized onset	32	69	126	
seizure and FBTCS				
Undetermined	2	8	34	
Seizure frequency in the last year				0.170
0-12	27	71	142	
13-52	3	14	16	
>52	6	8	14	
Unknown	5	6	28	
AEDs < or = 1	25	47	117	0.139
AEDs > or = 2	16	52	82	

1					
2					
3	Antiepileptic drugs				0.382
4					
5	Topiramate	10	21	35	
6					
7	Valproate	8	45	74	
8					
9	Levetiracetam	15	31	48	
10					
11	Oxcarbazepine	12	34	48	
12					
13	Migraine	16	26	36	0.010 ^a
14					

15
16 The continuous data are presented as mean \pm standard deviation.

17
18 ^a Bonferroni correction show statistical differences in grade 2-3 versus grade 0.

19
20 RLS, right-to-left shunt; FBTCS, focal to bilateral tonic-clonic seizures.


Table 3 Logistic regression analysis for migraine predictor

Characteristics	Odds ratio	95% confidence interval		P
		Lower	Upper	
Male	0.402	0.217	0.745	0.004
Age	1.038	1.010	1.067	0.007
Right-to-left shunt	2.544	1.392	4.650	0.002
Duration of epilepsy	1.023	0.987	1.061	0.214
Seizure frequency	1.082	0.811	1.443	0.593
Familial epilepsy	2.372	0.596	9.444	0.220
Valproate	1.300	0.752	2.248	0.347
Levetiracetam	0.914	0.483	1.731	0.782
Oxcarbazepine	0.741	0.386	1.420	0.366
Topiramate	1.639	0.806	3.333	0.173
Lamotrigine	0.551	0.142	2.146	0.390
Carbamazepine	0.768	0.373	1.582	0.474
Phenytoin	0.425	0.113	1.604	0.207
Phenobarbital	0.494	0.081	3.003	0.444

1
2
3
4
5
6
7 **Figure legends**
8

9 Figure 1. The flow diagram
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



sTable 1 Characteristics of migraine

Characteristics	N=78
Criteria	
Duration >2 hours (<18 years) or > 4 hours (\geq 18 years) ¹	78
At least 5 (without aura) attacks or 2 (with aura) attacks ¹	78
Headache has at least two of the following four characteristics	78
Location	
Left or Right ¹	46
Bilateral	32
Intensity ^{1,2}	
0-3	17
4-10 ¹	61
Pulsating quality ¹	53
Aggravation by or causing avoidance of routine physical activity ¹	51
During headache at least one of the following	78
Nausea and/or vomiting ¹	62
Photophobia and Phonophobia ¹	55

¹Diagnostic criteria of International Classification of Headache Disorders–3 criteria (beta)

²Visual analogue scale scores

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5,6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5,6
Bias	9	Describe any efforts to address potential sources of bias	6,11
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6,7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7,8
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	7
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7,8
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7,8
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9,10,11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The relationship between right-to-left shunt and migraine in patients with epilepsy: a single-centre, cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024144.R1
Article Type:	Research
Date Submitted by the Author:	07-Jul-2018
Complete List of Authors:	Zhang, Lin; Sichuan University West China Hospital, Department of Neurology Zhu, Xi; Sichuan University West China Hospital, Department of Neurology Qiu, XIangmiao; Sichuan University West China Hospital, Department of Neurology Li, Yajiao; Sichuan University West China Hospital, Department of Cardiology Chen, Yucheng; Sichuan University West China Hospital, Department of Cardiology Wang, Hui; Sichuan University West China Hospital, Department of Cardiology He, Shixu; Sichuan University West China Hospital, Department of Neurology Lai, Wanlin; Sichuan University West China Hospital, Department of Neurology Peng, Anjiao; Sichuan University West China Hospital, Department of Neurology Ning, Mingming; Cardio-Neurology Clinic, Massachusetts General Hospital, Harvard Medical School, Department of Neurology Chen, Lei; Sichuan University West China Medical Center, Department of Neurology
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Epidemiology
Keywords:	Epilepsy < NEUROLOGY, Migraine < NEUROLOGY, Right-to-left shunt

SCHOLARONE™
Manuscripts

1
2
3 **The relationship between right-to-left shunt and migraine in patients with**
4
5 **epilepsy: a single-centre, cross-sectional study**
6
7

8
9 Lin Zhang,¹ Xi Zhu,¹ Xiangmiao Qiu,¹ Yajiao Li,² Yucheng Chen,² Hui Wang,² Shixu
10
11 He,¹ Wanlin Lai,¹ Anjiao Peng,¹ Mingming Ning,³ Lei Chen¹
12
13

14
15 ¹Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
16

17
18 ²Department of Cardiology, West China Hospital, Sichuan University, Chengdu,
19
20 China
21

22
23 ³Department of Neurology, Cardio-Neurology Clinic, Massachusetts General Hospital,
24
25 Harvard Medical School, Boston, USA
26

27
28
29 Email for each author: Lin Zhang (zhanglinneur@163.com), Xi Zhu
30
31 (zhu61900@163.com), Xiangmiao Qiu (qiuxmiao@126.com), Yajiao Li
32
33 (liyajiao800@163.com), Yucheng Chen (chenyucheng2003@126.com), Hui Wang
34
35 (dashu1985723@163.com), Shixu He (274464077@qq.com), Wanlin Lai
36
37 (laiwl93@163.com), Anjiao Peng (peng_neurology@163.com), Mingming Ning
38
39 (Ning@hms.harvard.edu), Lei Chen (leilei_25@126.com)
40
41
42
43

44 Key words: right-to-left shunt; epilepsy; migraine
45

46 Number of words (main text): 2656
47
48
49
50
51
52
53
54
55
56
57

58 Corresponding to: Prof Lei Chen, Department of Neurology, West China Hospital, Sichuan University, No. 37
59 Guoxue Road, Chengdu, Sichuan Province, 610041, China. Tel: 13258178634. E-mail: leilei_25@126.com
60

ABSTRACT

Objectives To investigate the relationship between right-to-left shunt and migraine to account for the unexplained high prevalence of migraine in patients with epilepsy.

Design This is a cross-sectional study. The diagnosis and interview process of patients with migraine was based on the International Classification of Headache Disorders-3 beta in patients with epilepsy. Participants underwent transthoracic echocardiography (TTE) with contrast medium to identify right-to-left shunt. The highest number of microbubbles were recorded in the left atrium before the complete microbubble outflow of the right atrium. A moderate-to-large shunt was defined as the presence of 10 or more microbubbles.

Setting Single-centre, 2015-2017.

Participants Patients with epilepsy.

Primary and secondary outcome measures The primary outcome measures were the prevalence of migraine; the prevalence of right-to-left shunt in patients with migraine and those without migraine; and the prevalence of migraine in different degrees of shunting.

Results Three hundred thirty-nine participants with epilepsy who completed TTE were included in the analysis. The overall prevalence of migraine was 23.0%. One third of the migraineurs had mild right-to-left shunt and one fifth of the migraineurs had moderate-to-large right-to-left shunt. Patients with mild shunt did not have a higher prevalence of migraine than those without shunt (26.3% vs. 18.1%, $p = 0.102$); however, a higher prevalence of migraine was found in patients with moderate-to-large shunt (39.0% vs. 18.1%, odds ratio = 2.90, 95% confidence interval = 1.41 to 5.98, $p = 0.003$). Patients with migraine and patients without migraine had similar prevalence of mild shunt; however, patients with migraine had more

1
2 moderate-to-large shunt (20.5% vs. 9.6%, $p=0.002$). Right-to-left shunt and female
3
4 were factors predicting migraine prevalence.
5
6

7 **Conclusions** One fifth of migraineurs were correlated with moderate-to-large
8
9 right-to-left shunt, which could be an underlying cause of migraine in epilepsy.
10
11

12 13 **Strengths and limitations of this study**

- 14
15 ▶ Cohort study with data from a large number of patients with epilepsy.
- 16
17 ▶ We first studied the relationship between the degree of shunt and migraine in
18
19 patients with epilepsy.
- 20
21 ▶ Transthoracic echocardiography with contrast medium was used as a tool to detect
22
23 right-to-left shunt but not transoesophageal echocardiography.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

The comorbidity of migraine is common in patients with epilepsy. The lifetime occurrence of migraine was as high as 33.6% in patients with epilepsy, representing an overall 52% increase relative to people without epilepsy.^{1 2} Comorbid migraine may have an unfavourable effect on the prognosis of epilepsy in children and adults.^{3 4} Evidence of genetics and animal experiments have suggested similar pathophysiological mechanisms between migraine and familial epilepsy, such as genetic variants and abnormal neuronal excitability.⁵⁻⁹ Despite these findings, the mechanisms underlying migraine in patients with epilepsy are still controversial.

In the past 2 decades, right-to-left shunt, usually due to patent foramen ovale (PFO) and pulmonary arteriovenous shunt, have been found to be associated with migraine. A three-fold higher migraine with aura was observed in patients with right-to-left shunt compared to people without right-to-left shunt.¹⁰ There are clinical trials showing that treatment for right-to-left shunt can significantly reduce headache days although the responder rate defined as a 50% reduction in migraine attacks is not different from baseline.¹¹⁻¹⁴ In addition, the meta-analyses showed that a complete resolution of migraine after treatment for right-to-left shunt occurred in 54% of migraine-with-aura cases and in 39% of migraine-without-aura cases.^{15 16} Therefore, right-to-left shunt may be a fundamental cause of migraine. One of the possible mechanisms between the 2 conditions is that vasoactive chemicals triggering migraine bypass the pulmonary filter.⁵ Right-to-left shunt may carry microemboli into the carotid circulation. Animal experiments showed that microemboli can trigger the aura phenomenon by inducing cortical spreading depression (CSD).⁷

Similarly, right-to-left shunt may also induce migraine by vasoactive chemicals and microemboli in patients with epilepsy. Therefore, our main aim was to investigate

1
2
3 the relationship between right-to-left shunt and migraine to account for the
4 unexplained high prevalence of migraine in epilepsy. We also investigated other
5 migraine predictive factors, for example, sex, age, familial epilepsy, duration of
6 epilepsy and antiepileptic drugs (AEDs).
7
8
9
10

11 12 13 **METHODS**

14 **Study design and patients**

15
16 This is a cross-sectional study. Study populations were consecutively recruited
17 between June 2015 and December 2017 from the Department of Neurology, West
18 China Hospital, Sichuan University, China. Participants or legal guardians signed
19 informed consent. The inclusion criteria were as follows: (1) patients with epilepsy or
20 possible epilepsy (patients with possible epilepsy will be followed to establish the
21 diagnosis of epilepsy); and (2) the clinical history and medical records of epilepsy can
22 be obtained. The exclusion criteria were as follows: (1) age <3 years; (2) inaccurate
23 communication because of language problems; (3) patients with one seizure (because
24 high recurrence risk factors are controversial) and provoked seizures; (4) the
25 diagnosis of epilepsy was still undetermined when we performed the data analysis; (5)
26 the clinical history of epilepsy including onset age of seizure, AEDs, familial history
27 of epilepsy, seizure frequency in the last year, and types of seizure were not recorded;
28 (6) history of heart disease except right-to-left shunt; (7) right-to-left shunt confirmed
29 by transthoracic echocardiography (TTE) at another hospital (because there may be
30 differences between sonographers); (8) informed consent not signed; and (9) patients
31 did not complete the interview process for the diagnosis of migraine.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Definitions and collection of data**

56
57
58
59
60

1
2
3 A definitive diagnosis and classification of epilepsy met the criteria proposed by the
4 International League Against Epilepsy (ILAE) based on the clinical history, seizure
5 semiology, electroencephalography (EEG), and magnetic resonance imaging (MRI)
6 findings.¹⁷ For each patient, age, symptoms of seizure, onset age of seizure, AEDs,
7 education status, seizure onset with visual symptoms, history of febrile seizure,
8 seizure frequency in the last year, familial history of epilepsy, and types of seizure
9 (focal onset, focal to bilateral tonic-clonic seizures, or generalized onset) were
10 recorded.
11
12

13
14
15 The diagnosis and interview process for patients with migraine were based on the
16 International Classification of Headache Disorders (ICHD-3 beta).¹⁸ The number of
17 migraine attacks, estimated duration of migraine, location, quality, intensity (visual
18 analogue scale, 0-10), and aura were recorded. Patients would not be classified as
19 having migraine if only postictal and ictal migrainous headache occurred because
20 ICHD-3 beta does not have related criteria. Every patient was diagnosed by 2
21 neurologists separately. If the diagnosis of epilepsy and migraine was inconsistent, a
22 third senior neurologist was asked to discuss the case further.
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 For children, their parents (or the children themselves if they were old enough)
38 were asked to give specific information about epilepsy and migraine. Medical records
39 and seizure diaries during the last 12 months were reviewed to obtain information
40 regarding the history of epilepsy and migraine, EEG, and MRI.
41
42
43
44
45
46
47

48 **Transthoracic Echocardiography**

49
50 Participants underwent transthoracic echocardiography (TTE) with contrast medium
51 and 1-5 MHz or 3-8MHz multiplane transducers in Philips IE33 to identify
52 right-to-left shunt; this was performed by 2 experienced sonographers who also
53
54
55
56
57
58
59
60

1
2
3 analysed the videotapes together. Patients with other cardiac diseases (e.g., valvular
4 heart disease and cardiomyopathy) found by TTE were excluded. A microbubble
5 bolus of agitated solution of 9 mL saline and 1 mL air was injected into one side of
6 the patients' antecubital veins for increased sensitivity.^{19 20} Patients were assessed for
7 right-to-left shunt at rest and during the Valsalva manoeuvre and coughing. The
8 highest number of microbubbles were recorded in the left atrium before the complete
9 microbubble outflow of the right atrium. If 3 or more microbubbles appeared, a
10 right-to-left shunt was diagnosed. The degree of shunting was defined as grade 0 if 0
11 to 2 microbubbles occurred, grade 1 (mild) if 3 to 9 microbubbles occurred, grade 2
12 (moderate) if 10 to 30 microbubbles occurred and grade 3 (large) if more than 30
13 microbubbles occurred.²¹

24 25 26 27 28 **Data analysis**

29 Data were collected using the same standard forms in Microsoft Excel (version 2013).
30 Continuous variables were compared by analysis of variance (ANOVA). Categorical
31 variables were compared using the chi-square test or Fisher's exact test, as appropriate.
32 Bonferroni correction was used if necessary. Logistic regression analyses were used to
33 determine whether some variables were migraine-predicting factors. For all statistical
34 tests, $p < 0.05$ was determined to be statistically significant. Statistics were performed
35 using the SPSS statistical package (version 21.0).
36
37
38
39
40
41
42
43
44
45
46
47

48 **Patient and public involvement**

49 The development of the research question and outcome measures were informed by
50 published literature on PFO and migraine. Patients' priorities, experience and
51 preferences were not involved in designing the study. Patients who agreed to enrol to
52
53
54
55
56
57
58
59
60

1
2
3 the study received TTE. The recruitment process was mentioned in the Study Design
4 and Patients section. Two authors (Lin Zhang and Xi Zhu) disseminated the results to
5
6
7 the study participants by interviews.
8
9

10 11 **RESULTS**

12
13 We carefully interviewed 532 patients with seizure (s) or (and) their parents. One
14
15 hundred sixty-one patients were excluded. The reasons for exclusion are shown in
16
17 figure 1. Three hundred thirty-nine participants with epilepsy who completed the
18
19 interview process of migraine and TTE were included in the analysis. The details of
20
21 migraine features according to the ICHD-3 beta criteria are shown in Supplementary
22
23 file 1. The overall prevalence of migraine was 23.0% (table 1). A greater percentage
24
25 of females had migraines than males (28.8% vs. 17.2%, $p = 0.022$). Patients > 16
26
27 years seemed to have a higher prevalence of migraine than those ≤ 16 years of age
28
29 (25.7% vs. 11.0%, $p = 0.039$). If the duration of epilepsy was more than 10 years,
30
31 patients were more likely to have migraines (34.6% vs. 17.9%, $p = 0.001$). Patients
32
33 with polytherapy may have more migraines (28.0% vs. 19.0%, $p = 0.052$). Patients
34
35 with first-degree and second-degree relatives with epilepsy, as well as a history of
36
37 febrile seizures, may not have more migraines. Patients who have visual symptoms at
38
39 the onset of seizures did not have more migraines than those without visual symptoms
40
41 (data not shown).
42
43
44
45

46 One third of migraineurs have mild right-to-left shunt (table 1 and table 2). Patients
47
48 with mild right-to-left shunt did not have a higher prevalence of migraine than those
49
50 without right-to-left shunt (26.3% vs 18.1%, odds ratio = 1.61, 95% confidence
51
52 interval = 0.91 to 2.87, $p = 0.102$). In our cohort, 33.3% (26 of 78) of patients with
53
54 epilepsy and with migraine and 28.0% (73 of 261) of patients with epilepsy and
55
56
57
58
59
60

1
2
3 without migraine had mild right-to-left shunt ($p = 0.361$).

4
5 One fifth of migraineurs have moderate-to-large right-to-left shunt (table 1 and
6
7 table 2). Patients with moderate-to-large right-to-left shunt had a higher prevalence of
8
9 migraine than those without right-to-left shunt (39.0% vs. 18.1%, odds ratio = 2.90,
10
11 95% confidence interval = 1.41 to 5.98, $p = 0.003$). Twenty-one percent (16 of 78) of
12
13 patients with epilepsy and with migraine had moderate-to-large right-to-left shunt;
14
15 whereas only 10% (25 of 261) of patients with epilepsy and without migraine had
16
17 moderate-to-large right-to-left shunt (odds ratio = 2.44, 95% confidence interval =
18
19 1.23 to 4.84, $p=0.002$). After controlling for potential confounders, there are
20
21 significant differences of migraine prevalence between the groups with right-to-left
22
23 shunt grade 2-3 versus the group with right-to-left shunt grade 0 (table 2). Therefore,
24
25 moderate-to-large right-to-left shunt but not mild right-to-left shunt was associated
26
27 with migraine in patients with epilepsy.
28
29

30
31 We used a logistic regression analysis to identify the possible factors predicting
32
33 migraine prevalence, such as gender, duration of epilepsy, current age, right-to-left
34
35 shunt and number of antiepileptic drugs (table 3). Right-to-left shunt and female were
36
37 factors predicting migraine prevalence. Although patients with duration of
38
39 epilepsy >10 years and older age have a higher migraine prevalence (table 1), the
40
41 logistic regression analysis showed no significant statistical difference.
42
43

44 PFO closure were performed in 7 patients. Four patients were followed for 6
45
46 months. We found that PFO closure fully controlled migraine in 2 of 4 cases. Before
47
48 PFO closure, the two patients have more than 11 migraine attacks in the last year.
49
50 More interesting, the frequency of seizures in 3 patients with migraine after PFO
51
52 closure decreased significantly.
53
54
55
56
57
58
59
60

DISCUSSION

This is the first study to evaluate the relationship between migraine and right-to-left shunt in a large number of patients with epilepsy. Our main findings were as follows:

1) one third of the migraineurs have mild right-to-left shunt and one fifth of the migraineurs have moderate-to-large right-to-left shunt; 2) patients with mild right-to-left shunt did not have a higher prevalence of migraine than those without right-to-left shunt; 3) moderate-to-large right-to-left shunt was associated with migraine in patients with epilepsy and 4) right-to-left shunt and female were factors predicting migraine prevalence in patients with epilepsy.

Migraine in patients without epilepsy has been proved to be associated with CSD and activation of the trigeminovascular system and its constituent neuropeptides.²² In addition, recent studies also suggested the cortical excitatory/inhibitory imbalance due to neuronal and glial ion channels renders patients more vulnerable to an headache attack.²² Migraine in patients with epilepsy is not only associated with the aforementioned mechanisms, but also is usually considered to be associated with abnormal neuronal excitability induced by genetic variants.⁵⁻⁹ However, the high prevalence of migraine in patients with epilepsy cannot be fully explained by genetic variants. In the past 2 decades, right-to-left shunt have been found to be associated with migraine in patients without epilepsy. Our major hypothesis was that right-to-left shunt may also be one of the pathophysiological mechanisms of migraine in patients with epilepsy. The results showed that mild right-to-left shunt was not associated with migraine in patients with epilepsy. Almost one fifth of migraine were correlated with moderate-to-large right-to-left shunt, which could be an underlying cause of migraine in epilepsy. The mechanisms of the relationship between moderate-to-large right-to-left shunt and migraine remains speculative. A previous study showed that

1
2
3 larger right-to-left shunt tend to trigger migraine attacks because of the increased
4 extent of the shunt.²³ Larger shunt allow harmful circulatory factors, such as
5 vasoactive substances and microemboli which are eliminated by lung, to bypass the
6 pulmonary filter and travel directly from the venous to the cerebral artery.
7 Right-to-left shunt and higher rates of Doppler-detected cerebral microemboli have
8 been reported to be associated.²⁴ In an animal experiment, air microemboli are able to
9 trigger CSD and migraine aura often with transient microvascular occlusion that is
10 insufficient to cause a permanent ischemic lesion.⁷ In humans, diagnostic microbubble
11 injection also induced attacks of migraine with aura.²⁵ Therefore, microemboli may be
12 a key role linking CSD, migraine, and moderate-to-large shunt.
13
14
15
16
17
18
19
20
21
22
23

24 Interestingly, CSD increases neuronal excitability and triggers ictiform activity in
25 neuronal tissues with partial impairment of inhibitory.⁹ CSD also triggers migraine
26 headache by activating neuronal Panx1 channels, which contributes to neuronal
27 hyperactivity in seizures.^{26,27} These findings may explain why migraine may have an
28 unfavourable effect on the prognosis of epilepsy.^{3,4} Therefore, moderate-to-large
29 right-to-left shunt may not only be an underlying cause of migraine but also an
30 adverse prognostic factor in patients with epilepsy. Whether moderate-to-large
31 right-to-left shunt is an adverse prognostic factors in epilepsy should also be
32 investigated.
33
34
35
36
37
38
39
40
41
42
43

44 The effect of PFO closure for migraine treatment still remains controversial.
45 Randomised controlled trials (RCTs) looking at the effect of PFO closure on migraine
46 were initially conducted. There are clinical trials showing that treatment for
47 right-to-left shunt did not increase responder rate defined as 50% reduction in
48 migraine attacks; however, it significantly reduced headache days.¹¹⁻¹⁴ Similarly to the
49 stroke trials, they had initial negative RCTs. With better patient selection and longer
50
51
52
53
54
55
56
57
58
59
60

1
2
3 follow-up, subsequent trials may show more cessation of migraine headache.²⁸ In our
4 cohort, we found that PFO closure fully controlled migraine in 2 of 4 cases. More
5 interesting, the frequency of seizures in 3 patients with migraine after surgery
6 decreased significantly. Although these cases need to be explained with caution, it is
7 worth investigating in the future whether PFO closure improve migraine attacks and
8 seizure outcomes. In addition, given the subjective nature of migraines and their
9 vulnerability to bias and the placebo effect, perhaps a large, well-designed sham
10 controlled trial with modern devices is required. If treatment for right-to-left shunt
11 have been shown to be definitely effective, right-to-left shunt should be screened in
12 patients with epilepsy and with migraine.
13
14
15
16
17
18
19
20
21
22
23

24 This study has some limitations. First, transoesophageal echocardiography (TEE) is
25 a gold standard diagnostic tool with a sensitivity and specificity of 80% to 100% for
26 the detection of a right-to-left shunt.^{19 20} The contrast TTE used by us has a lower
27 sensitivity than TEE.¹⁹ However, harmonic imaging improves sensitivity for the
28 detection of right-to-left shunt, ranging from 66% to 100%.^{19 20 29 30} In addition, TTE
29 is not inferior to TEE in the assessment of large shunt because TEE may miss large
30 shunt detected by TTE.³⁰ In our study, moderate-to-large right-to-left shunt are more
31 likely to be associated with migraine; therefore, TTE may not be an inferior choice to
32 TEE. Second, the population may be biased because a few patients did not complete
33 TTE. However, there were no differences in demographic characteristics between
34 patients who did or did not refuse TTE and the conclusions of our study should not be
35 affected. Third, only Chinese people were recruited, and this limits the
36 generalizability of results.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 CONCLUSIONS

56
57
58
59
60

1
2
3 Moderate-to-large right-to-left shunt but not mild right-to-left shunt were associated
4 with migraine. On the basis of these results, patients with epilepsy and with migraine
5 should be screened for a right-to-left shunt if treatment for a right-to-left shunt has
6 been shown to be effective in migraine. Whether moderate-to-large right-to-left shunt
7 is an adverse prognostic factor in epilepsy should be also investigated.
8
9
10
11
12

13
14
15
16 **Acknowledgements** No patient advisers were involved in the study. We thank Dr. Qi
17 Si for her help.
18
19
20
21

22 **Contributors** Lei Chen and Mingming Ning conceived and designed the work. Lin
23 Zhang and Xi Zhu were involved in data collection, data analysis and interpretation.
24 Lin Zhang drafted the manuscript. Lei Chen involved in critical revision of the article
25 and final approval of the version to be published. Xiangmiao Qiu, Xiangmiao Qiu,
26 Shixu He, Anjiao Peng, Wanlin Lai, Yajiao Li, Yucheng Chen, and Hui Wang were
27 involved in the data collection and final approval of the version to be published. All
28 authors have agreed to be accountable for all aspects of the work.
29
30
31
32
33
34
35
36
37
38

39 **Funding** Funding for this study was provided by China Association Against Epilepsy
40 (No.2016005).
41
42
43
44
45

46 **Competing interests** None declared.
47
48
49

50 **Patient consent** Obtained.
51
52
53

54 **Ethics approval** The protocol was approved by the Ethics Committee of the West
55
56
57
58
59
60

1
2
3 China Hospital of Sichuan University.
4
5
6

7 **Data sharing statement** No additional data available.
8
9

10
11 **REFERENCES**
12
13

- 14 1. Keezer MR, Bauer PR, Ferrari MD, *et al*. The comorbid relationship between
15 migraine and epilepsy: a systematic review and meta-analysis. *Eur J Neurol*
16 2015;22:1038-47.
17
18 2. Le H, Tfelt-Hansen P, Russell MB, *et al*. Co-morbidity of migraine with
19 somatic disease in a large population-based study. *Cephalalgia* 2011;31:43-64.
20
21 3. Dragoumi P, Tzetzis O, Vargiami E, *et al*. Clinical course and seizure outcome
22 of idiopathic childhood epilepsy: determinants of early and long-term
23 prognosis. *BMC Neurol* 2013;13:206.
24
25 4. Velioglu SK, Boz C, Ozmenoglu M. The impact of migraine on epilepsy: a
26 prospective prognosis study. *Cephalalgia* 2005;25:528-35.
27
28 5. Finocchi C, Del Sette M. Migraine with aura and patent foramen ovale: myth
29 or reality? *Neurol Sci* 2015;36 Suppl 1:61-6.
30
31 6. Ludvigsson P, Hesdorffer D, Olafsson E, *et al*. Migraine with aura is a risk
32 factor for unprovoked seizures in children. *Ann Neurol* 2006;59:210-3.
33
34 7. Nozari A, Dilekoz E, Sukhotinsky I, *et al*. Microemboli may link spreading
35 depression, migraine aura, and patent foramen ovale. *Ann Neurol*
36 2010;67:221-9.
37
38 8. Winawer MR, Connors R. Evidence for a shared genetic susceptibility to
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- migraine and epilepsy. *Epilepsia* 2013;54:288-95.
9. Eickhoff M, Kovac S, Shahabi P, *et al.* Spreading depression triggers ictiform activity in partially disinhibited neuronal tissues. *Exp Neurol* 2014;253:1-15.
 10. Wammes-van der Heijden EA, Tijssen CC, Egberts AC. Right-to-left shunt and migraine: the strength of the relationship. *Cephalalgia* 2006;26:208-13.
 11. Xing YQ, Guo YZ, Gao YS, *et al.* Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine (EASTFORM) Trial. *Sci Rep* 2016;6:39081.
 12. Tobis JM, Charles A, Silberstein SD, *et al.* Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial. *J Am Coll Cardiol* 2017;70:2766-74.
 13. Dowson A, Mullen MJ, Peatfield R, *et al.* Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. *Circulation* 2008;117:1397-404.
 14. Mattle HP, Evers S, Hildick-Smith D, *et al.* Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. *Eur Heart J* 2016;37:2029-36.
 15. Kanwar SM, Noheria A, DeSimone CV, *et al.* Coincidental Impact of Transcatheter Patent Foramen Ovale Closure on Migraine with and without Aura - A Comprehensive Meta-Analysis. *Clin Trials Regul Sci Cardiol*

- 2016;15:7-13.
16. Shi YJ, Lv J, Han XT, *et al.* Migraine and percutaneous patent foramen ovale closure: a systematic review and meta-analysis. *BMC Cardiovasc Disord* 2017;17:203.
17. Fisher RS, Cross JH, French JA, *et al.* Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia* 2017;58:522-30.
18. Ettl DA. The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia* 2013;33:629-808.
19. Cotter PE, Martin PJ, Belham M. Improved sensitivity of transthoracic contrast echocardiography in the detection of right-to-left shunts. *J Am Soc Echocardiogr* 2010;23:578; author reply 78-9.
20. Ha JW, Shin MS, Kang S, *et al.* Enhanced detection of right-to-left shunt through patent foramen ovale by transthoracic contrast echocardiography using harmonic imaging. *Am J Cardiol* 2001;87:669-71.
21. Mas JL, Arquizan C, Lamy C, *et al.* Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. *N Engl J Med* 2001;345:1740-6.
22. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. *Annu Rev Physiol* 2013;75:365-91.
23. Tembl J, Lago A, Sevilla T, *et al.* Migraine, patent foramen ovale and

- 1
2
3 migraine triggers. *J Headache Pain* 2007;8:7-12.
4
5
6 24. Rodriguez RA, Sinclair B, Weatherdon D, *et al.* Patent foramen ovale and
7
8 brain microembolization during scoliosis surgery in adolescents. *Spine (Phila*
9
10 *Pa 1976)* 2001;26:1719-21.
11
12
13 25. Dinia L, Roccatagliata L, Bonzano L, *et al.* Diffusion MRI during migraine
14
15 with aura attack associated with diagnostic microbubbles injection in subjects
16
17 with large PFO. *Headache* 2007;47:1455-6.
18
19
20 26. Karatas H, Erdener SE, Gursoy-Ozdemir Y, *et al.* Spreading depression
21
22 triggers headache by activating neuronal Panx1 channels. *Science*
23
24 2013;339:1092-5.
25
26
27 27. Santiago MF, Veliskova J, Patel NK, *et al.* Targeting pannexin1 improves
28
29 seizure outcome. *PLoS One* 2011;6:e25178.
30
31
32 28. Mojadidi MK, Zaman MO, Elgendy IY, *et al.* Cryptogenic Stroke and Patent
33
34 Foramen Ovale. *J Am Coll Cardiol* 2018;71:1035-43.
35
36
37 29. Clarke NR, Timperley J, Kelion AD, *et al.* Transthoracic echocardiography
38
39 using second harmonic imaging with Valsalva manoeuvre for the detection of
40
41 right to left shunts. *Eur J Echocardiogr* 2004;5:176-81.
42
43
44 30. Daniels C, Weytjens C, Cosyns B, *et al.* Second harmonic transthoracic
45
46 echocardiography: the new reference screening method for the detection of
47
48 patent foramen ovale. *Eur J Echocardiogr* 2004;5:449-52.
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Migraine prevalence in different groups

Characteristics	Sample	Migraine (%)	P values
Gender			0.022
Male	169	29 (17.2)	
Female	170	49 (28.8)	
Current age, years			0.039
≤16	82	12 (11.0)	
>16	257	66 (25.7)	
Duration of epilepsy, years			0.001
≤10	235	42 (17.9)	
>10	104	36 (34.6)	
Onset age, years			0.421
≤16	183	39 (21.3)	
>16	156	39 (25.0)	
Seizure frequency in the last year			0.256
0-12	246	56 (22.8)	
13-52	33	11 (33.3)	
>52	28	7 (25.0)	
Unknown	32	4 (12.5)	
Number of AEDs			0.052
< or = 1	189	36 (19.0)	
> or = 2	150	42 (28.0)	
AEDs			0.299
Topiramate	66	20 (30.3)	
Valproate	126	29 (23.0)	

1				
2				
3	Levetiracetam	94	26 (27.7)	
4				
5	Oxcarbazepine	94	19 (20.2)	
6				
7	Lamotrigine	27	2 (7.4)	
8				
9	Carbamazepine	67	19 (28.4)	
10				
11	Phenytoin	20	4 (20.0)	
12				
13	Phenobarbital	12	2 (16.7)	
14				
15	Seizure types			0.319
16				
17	Focal onset seizure	68	10 (14.7)	
18				
19	Generalized onset seizure and focal	227	58 (25.6)	
20				
21	to bilateral tonic-clonic seizures			
22				
23	Undetermined	44	10 (22.7)	
24				
25	Familial epilepsy	11	5 (45.5)	0.135
26				
27	First-degree relatives	9	4 (44.4)	
28				
29	Second-degree relatives	2	1 (50.0)	
30				
31	No familial epilepsy	328	73 (22.3)	
32				
33	Right-to-left shunt			
34				
35	Grade 1	99	26 (26.3)	0.102
36				
37	Grade 2-3	41	16 (39.0)	0.003
38				
39	Grade 1-3	140	42 (29.6)	0.010
40				
41	Grade 0	199	36 (18.1)	
42				
43				
44				
45				

AEDs, antiepileptic drugs.

Table 2 High prevalence of migraine in patients with moderate to large right-to-left shunt

Characteristics	Right-to-left shunt			P
	Grade 2-3 (n=41)	Grade 1 (n=99)	Grade 0 (n=199)	
Male, n (%)	17 (41.5)	52 (52.5)	100 (50.3)	0.413
Age, years	26.9 ± 11.7	27.6 ± 13.7	26.4 ± 13.2	0.769
Onset age, years	19.3 ± 11.2	17.9 ± 12.4	17.8 ± 12.3	0.779
Duration, years	8.1 ± 8.9	9.7 ± 9.6	8.7 ± 9.1	0.580
Familial epilepsy, n (%)	2	2	7	0.648
Education, n (%)				0.772
0-6, years	13 (31.7)	24 (24.2)	52 (26.1)	
7-12, years	20 (48.8)	47 (47.5)	104 (52.3)	
≥13, years	8 (19.5)	28 (28.3)	43 (21.6)	
Seizure types, n (%)				0.085
Focal onset	7 (17.1)	22 (22.2)	39 (19.6)	
Generalized onset seizure and focal to bilateral tonic-clonic seizures	32 (78.0)	69 (69.7)	126 (63.3)	
Undetermined	2 (4.9)	8 (8.1)	34 (17.1)	
Seizure frequency in the last year, n (%)				0.284
0-12	27 (65.9)	71 (71.7)	148 (71.4)	
13-52	3 (7.3)	14 (14.1)	16 (8.0)	
>52	6 (14.6)	8 (8.1)	14 (7.0)	

Unknown	5 (12.2)	6 (6.1)	21 (14.1)	
Number of used AEDs				0.139
< or = 1, n (%)	25 (61.0)	47 (47.5)	117 (58.8)	
> or = 2, n (%)	16 (39.0)	52 (52.5)	82 (41.2)	
AEDs				0.735
Topiramate	10	21	35	
Valproate	8	45	74	
Levetiracetam	15	31	48	
Oxcarbazepine	12	34	48	
Lamotrigine	4	8	15	
Carbamazepine	8	28	31	
Phenytoin	1	6	13	
Phenobarbital	1	4	7	
Migraine, n (%)	16 (39.0)	26 (26.3)	36 (18.1)	0.010 ^a

The continuous data are presented as mean \pm standard deviation.

^a Bonferroni correction show statistical differences in grade 2-3 versus grade 0.

AEDs, antiepileptic drugs.

Table 3 Logistic regression analysis for migraine predictors

Characteristics	Odds ratio	95% confidence interval		P
		Lower	Upper	
Male	0.518	0.302	0.891	0.017
Current age, years	0.978	0.956	1.001	0.057
Right-to-left shunt	2.200	1.274	3.797	0.005
Duration of epilepsy, years	0.974	0.945	1.004	0.085
Familial epilepsy	2.828	0.765	10.453	0.119
Number of antiepileptic drugs > 1	1.354	0.784	2.340	0.277

Figure legends

Figure 1. The flow diagram




Figure 1. The flow diagram

136x127mm (300 x 300 DPI)

sTable 1 Characteristics of migraine

Characteristics	N=78
Criteria	
Duration >2 hours (<18 years) or > 4 hours (\geq 18 years) ¹	78
At least 5 (without aura) attacks or 2 (with aura) attacks ¹	78
Headache has at least two of the following four characteristics	78
Location	
Left or Right ¹	46
Bilateral	32
Intensity^{1,2}	
0-3	17
4-10 ¹	61
Pulsating quality ¹	53
Aggravation by or causing avoidance of routine physical activity ¹	51
During headache at least one of the following	
Nausea and/or vomiting ¹	62
Photophobia and Phonophobia ¹	55

¹Diagnostic criteria of International Classification of Headache Disorders–3 criteria (beta)

²Visual analogue scale scores

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5,6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5,6
Bias	9	Describe any efforts to address potential sources of bias	6,11
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6,7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7,8
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	7
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7,8
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7,8
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9,10,11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The relationship between right-to-left shunt and migraine in patients with epilepsy: a single-centre, cross-sectional study in China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024144.R2
Article Type:	Research
Date Submitted by the Author:	28-Jul-2018
Complete List of Authors:	Zhang, Lin; Sichuan University West China Hospital, Department of Neurology Zhu, Xi; Sichuan University West China Hospital, Department of Neurology Qiu, XIangmiao; Sichuan University West China Hospital, Department of Neurology Li, Yajiao; Sichuan University West China Hospital, Department of Cardiology Chen, Yucheng; Sichuan University West China Hospital, Department of Cardiology Wang, Hui; Sichuan University West China Hospital, Department of Cardiology He, Shixu; Sichuan University West China Hospital, Department of Neurology Lai, Wanlin; Sichuan University West China Hospital, Department of Neurology Peng, Anjiao; Sichuan University West China Hospital, Department of Neurology Ning, Mingming; Cardio-Neurology Clinic, Massachusetts General Hospital, Harvard Medical School, Department of Neurology Chen, Lei; Sichuan University West China Medical Center, Department of Neurology
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Epidemiology
Keywords:	Epilepsy < NEUROLOGY, Migraine < NEUROLOGY, Right-to-left shunt

SCHOLARONE™
Manuscripts

1
2
3 **The relationship between right-to-left shunt and migraine in patients with**
4
5 **epilepsy: a single-centre, cross-sectional study in China**
6
7
8

9 Lin Zhang,¹ Xi Zhu,¹ Xiangmiao Qiu,¹ Yajiao Li,² Yucheng Chen,² Hui Wang,² Shixu
10 He,¹ Wanlin Lai,¹ Anjiao Peng,¹ Mingming Ning,³ Lei Chen¹
11
12
13

14
15
16 ¹Department of Neurology, West China Hospital, Sichuan University, Chengdu, China

17
18 ²Department of Cardiology, West China Hospital, Sichuan University, Chengdu,
19
20 China

21
22 ³Department of Neurology, Cardio-Neurology Clinic, Massachusetts General Hospital,
23
24 Harvard Medical School, Boston, USA
25

26
27
28 Email for each author: Lin Zhang (zhanglinneur@163.com), Xi Zhu
29
30 (zhu61900@163.com), Xiangmiao Qiu (qiuxmiao@126.com), Yajiao Li
31
32 (liyajiao800@163.com), Yucheng Chen (chenyucheng2003@126.com), Hui Wang
33
34 (dashu1985723@163.com), Shixu He (274464077@qq.com), Wanlin Lai
35
36 (laiwl93@163.com), Anjiao Peng (peng_neurology@163.com), Mingming Ning
37
38 (Ning@hms.harvard.edu), Lei Chen (leilei_25@126.com)
39
40
41
42
43

44 Key words: right-to-left shunt; epilepsy; migraine
45

46 Number of words (main text): 2644
47
48
49
50
51
52
53
54
55
56
57

ABSTRACT

Objectives To investigate the relationship between right-to-left shunt and migraine to account for the unexplained high prevalence of migraine in patients with epilepsy.

Design This is a cross-sectional study. The diagnosis and interview process of patients with migraine was based on the International Classification of Headache Disorders-3 beta in patients with epilepsy. Participants underwent transthoracic echocardiography (TTE) with contrast medium to identify right-to-left shunt. The highest number of microbubbles were recorded in the left atrium before the complete microbubble outflow of the right atrium. A moderate-to-large shunt was defined as the presence of 10 or more microbubbles.

Setting A single-centre, cross-sectional study in China, 2015-2017.

Participants Patients with epilepsy.

Primary and secondary outcome measures The primary outcome measures were the prevalence of migraine; the prevalence of right-to-left shunt in patients with migraine and those without migraine; and the prevalence of migraine in different degrees of shunting.

Results Three hundred thirty-nine participants with epilepsy who completed TTE were included in the analysis. The overall prevalence of migraine was 23.0%. One third of the migraineurs had mild right-to-left shunt and one fifth of the migraineurs had moderate-to-large right-to-left shunt. Patients with mild shunt did not have a higher prevalence of migraine than those without shunt (26.3% vs. 18.1%, $p = 0.102$); however, a higher prevalence of migraine was found in patients with moderate-to-large shunt (39.0% vs. 18.1%, odds ratio = 2.90, 95% confidence interval = 1.41 to 5.98, $p = 0.003$). Patients with migraine and patients without migraine had similar prevalence of mild shunt; however, patients with migraine had more

1
2
3 moderate-to-large shunt (20.5% vs. 9.6%, $p=0.002$). Right-to-left shunt and female
4
5 were factors predicting migraine prevalence.
6

7 **Conclusions** One fifth of migraineurs were correlated with moderate-to-large
8
9 right-to-left shunt, which could be an underlying cause of migraine in epilepsy.
10
11

12 13 **Strengths and limitations of this study**

- 14
15 ▶ Cohort study with data from a large number of patients with epilepsy.
- 16
17 ▶ We first studied the relationship between the degree of shunt and migraine in
18
19 patients with epilepsy.
- 20
21 ▶ Transthoracic echocardiography with contrast medium was used as a tool to detect
22
23 right-to-left shunt but not transoesophageal echocardiography.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

The comorbidity of migraine is common in patients with epilepsy. The lifetime occurrence of migraine was as high as 33.6% in patients with epilepsy, representing an overall 52% increase relative to people without epilepsy.^{1 2} Comorbid migraine may have an unfavourable effect on the prognosis of epilepsy in children and adults.^{3 4} Evidence of genetics and animal experiments have suggested similar pathophysiological mechanisms between migraine and familial epilepsy, such as genetic variants and abnormal neuronal excitability.⁵⁻⁹ Despite these findings, the mechanisms underlying migraine in patients with epilepsy are still controversial.

In the past 2 decades, right-to-left shunt, usually due to patent foramen ovale (PFO) and pulmonary arteriovenous shunt, have been found to be associated with migraine. A three-fold higher migraine with aura was observed in patients with right-to-left shunt compared to people without right-to-left shunt.¹⁰ There are clinical trials showing that treatment for right-to-left shunt can significantly reduce headache days although the responder rate defined as a 50% reduction in migraine attacks is not different from baseline.¹¹⁻¹⁴ In addition, the meta-analyses showed that a complete resolution of migraine after treatment for right-to-left shunt occurred in 54% of migraine-with-aura cases and in 39% of migraine-without-aura cases.^{15 16} Therefore, right-to-left shunt may be a fundamental cause of migraine. One of the possible mechanisms between the 2 conditions is that vasoactive chemicals triggering migraine bypass the pulmonary filter.⁵ Right-to-left shunt may carry microemboli into the carotid circulation. Animal experiments showed that microemboli can trigger the aura phenomenon by inducing cortical spreading depression (CSD).⁷

Similarly, right-to-left shunt may also induce migraine by vasoactive chemicals and microemboli in patients with epilepsy. Therefore, our main aim was to investigate

1
2
3 the relationship between right-to-left shunt and migraine to account for the
4 unexplained high prevalence of migraine in epilepsy. We also investigated other
5 migraine predictive factors, for example, sex, age, familial epilepsy, duration of
6 epilepsy and antiepileptic drugs (AEDs).
7
8
9
10

11 12 13 **METHODS**

14 **Study design and patients**

15
16 This is a cross-sectional study. Study populations were consecutively recruited
17 between June 2015 and December 2017 from the Department of Neurology, West
18 China Hospital, Sichuan University, China. Participants or legal guardians signed
19 informed consent. The inclusion criteria were as follows: (1) patients with epilepsy or
20 possible epilepsy (patients with possible epilepsy will be followed to establish the
21 diagnosis of epilepsy); and (2) the clinical history and medical records of epilepsy can
22 be obtained. The exclusion criteria were as follows: (1) age <3 years; (2) inaccurate
23 communication because of language problems; (3) patients with one seizure (because
24 high recurrence risk factors are controversial) and provoked seizures; (4) the
25 diagnosis of epilepsy was still undetermined when we performed the data analysis; (5)
26 the clinical history of epilepsy including onset age of seizure, AEDs, familial history
27 of epilepsy, seizure frequency in the last year, and types of seizure were not recorded;
28 (6) history of heart disease except right-to-left shunt; (7) right-to-left shunt confirmed
29 by transthoracic echocardiography (TTE) at another hospital (because there may be
30 differences between sonographers); (8) informed consent not signed; and (9) patients
31 did not complete the interview process for the diagnosis of migraine.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Definitions and collection of data**

56
57
58
59
60

1
2
3 A definitive diagnosis and classification of epilepsy met the criteria proposed by the
4 International League Against Epilepsy (ILAE) based on the clinical history, seizure
5 semiology, electroencephalography (EEG), and magnetic resonance imaging (MRI)
6 findings.¹⁷ For each patient, age, symptoms of seizure, onset age of seizure, AEDs,
7 education status, seizure onset with visual symptoms, history of febrile seizure,
8 seizure frequency in the last year, familial history of epilepsy, and types of seizure
9 (focal onset, focal to bilateral tonic-clonic seizures, or generalized onset) were
10 recorded.
11
12
13
14
15
16
17
18
19

20 The diagnosis and interview process for patients with migraine were based on the
21 International Classification of Headache Disorders (ICHD-3 beta).¹⁸ The number of
22 migraine attacks, estimated duration of migraine, location, quality, intensity (visual
23 analogue scale, 0-10), and aura were recorded. Patients would not be classified as
24 having migraine if only postictal and ictal migrainous headache occurred because
25 ICHD-3 beta does not have related criteria. Every patient was diagnosed by 2
26 neurologists separately. If the diagnosis of epilepsy and migraine was inconsistent, a
27 third senior neurologist was asked to discuss the case further.
28
29
30
31
32
33
34
35
36

37 For children, their parents (or the children themselves if they were old enough)
38 were asked to give specific information about epilepsy and migraine. Medical records
39 and seizure diaries during the last 12 months were reviewed to obtain information
40 regarding the history of epilepsy and migraine, EEG, and MRI.
41
42
43
44
45
46
47

48 **Transthoracic Echocardiography**

49

50 Participants underwent transthoracic echocardiography (TTE) with contrast medium
51 and 1-5 MHz or 3-8MHz multiplane transducers in Philips IE33 to identify
52 right-to-left shunt; this was performed by 2 experienced sonographers who also
53
54
55
56
57
58
59
60

1
2
3 analysed the videotapes together. Patients with other cardiac diseases (e.g., valvular
4 heart disease and cardiomyopathy) found by TTE were excluded. A microbubble
5 bolus of agitated solution of 9 mL saline and 1 mL air was injected into one side of
6 the patients' antecubital veins for increased sensitivity.^{19 20} Patients were assessed for
7 right-to-left shunt at rest and during the Valsalva manoeuvre and coughing. The
8 highest number of microbubbles were recorded in the left atrium before the complete
9 microbubble outflow of the right atrium. If 3 or more microbubbles appeared, a
10 right-to-left shunt was diagnosed. The degree of shunting was defined as grade 0 if 0
11 to 2 microbubbles occurred, grade 1 (mild) if 3 to 9 microbubbles occurred, grade 2
12 (moderate) if 10 to 30 microbubbles occurred and grade 3 (large) if more than 30
13 microbubbles occurred.²¹

24 25 26 27 28 **Data analysis**

29 Data were collected using the same standard forms in Microsoft Excel (version 2013).
30 Continuous variables were compared by analysis of variance (ANOVA). Categorical
31 variables were compared using the chi-square test or Fisher's exact test, as appropriate.
32 Bonferroni correction was used if necessary. Logistic regression analyses were used to
33 determine whether some variables were migraine-predicting factors. For all statistical
34 tests, $p < 0.05$ was determined to be statistically significant. Statistics were performed
35 using the SPSS statistical package (version 21.0).
36
37
38
39
40
41
42
43
44
45
46
47

48 **Patient and public involvement**

49 The development of the research question and outcome measures were informed by
50 published literature on PFO and migraine. Patients' priorities, experience and
51 preferences were not involved in designing the study. Patients who agreed to enrol to
52
53
54
55
56
57
58
59
60

1
2
3 the study received TTE. Two authors (Lin Zhang and Xi Zhu) disseminated the results
4
5 to the study participants by interviews.
6
7

8 9 **RESULTS**

10
11 We carefully interviewed 532 patients with seizure (s) or (and) their parents. One
12
13 hundred sixty-one patients were excluded. The reasons for exclusion are shown in
14
15 figure 1. Three hundred thirty-nine participants with epilepsy who completed the
16
17 interview process of migraine and TTE were included in the analysis. The details of
18
19 migraine features according to the ICHD-3 beta criteria are shown in Supplementary
20
21 file 1. The overall prevalence of migraine was 23.0% (table 1). A greater percentage
22
23 of females had migraines than males (28.8% vs. 17.2%, $p = 0.022$). Patients > 16
24
25 years seemed to have a higher prevalence of migraine than those ≤ 16 years of age
26
27 (25.7% vs. 11.0%, $p = 0.039$). If the duration of epilepsy was more than 10 years,
28
29 patients were more likely to have migraines (34.6% vs. 17.9%, $p = 0.001$). Patients
30
31 with polytherapy may have more migraines (28.0% vs. 19.0%, $p = 0.052$). Patients
32
33 with first-degree and second-degree relatives with epilepsy, as well as a history of
34
35 febrile seizures, may not have more migraines. Patients who have visual symptoms at
36
37 the onset of seizures did not have more migraines than those without visual symptoms
38
39 (data not shown).
40
41
42
43

44 One third of migraineurs have mild right-to-left shunt (table 1 and table 2). Patients
45
46 with mild right-to-left shunt did not have a higher prevalence of migraine than those
47
48 without right-to-left shunt (26.3% vs 18.1%, odds ratio = 1.61, 95% confidence
49
50 interval = 0.91 to 2.87, $p = 0.102$). In our cohort, 33.3% (26 of 78) of patients with
51
52 epilepsy and with migraine and 28.0% (73 of 261) of patients with epilepsy and
53
54 without migraine had mild right-to-left shunt ($p = 0.361$).
55
56
57
58
59
60

1
2
3 One fifth of migraineurs have moderate-to-large right-to-left shunt (table 1 and
4 table 2). Patients with moderate-to-large right-to-left shunt had a higher prevalence of
5 migraine than those without right-to-left shunt (39.0% vs. 18.1%, odds ratio = 2.90,
6 95% confidence interval = 1.41 to 5.98, $p = 0.003$). Twenty-one percent (16 of 78) of
7 patients with epilepsy and with migraine had moderate-to-large right-to-left shunt;
8 whereas only 10% (25 of 261) of patients with epilepsy and without migraine had
9 moderate-to-large right-to-left shunt (odds ratio = 2.44, 95% confidence interval =
10 1.23 to 4.84, $p=0.002$). After controlling for potential confounders, there are
11 significant differences of migraine prevalence between the groups with right-to-left
12 shunt grade 2-3 versus the group with right-to-left shunt grade 0 (table 2). Therefore,
13 moderate-to-large right-to-left shunt but not mild right-to-left shunt was associated
14 with migraine in patients with epilepsy.
15
16
17
18
19
20
21
22
23
24
25
26
27

28 We used a logistic regression analysis to identify the possible factors predicting
29 migraine prevalence, such as gender, duration of epilepsy, current age, right-to-left
30 shunt and number of antiepileptic drugs (table 3). Right-to-left shunt and female were
31 factors predicting migraine prevalence. Although patients with duration of
32 epilepsy >10 years and older age have a higher migraine prevalence (table 1), the
33 logistic regression analysis showed no significant statistical difference.
34
35
36
37
38
39
40
41

42 PFO closure were performed in 7 patients. Four patients were followed for 6
43 months. We found that PFO closure fully controlled migraine in 2 of 4 cases. Before
44 PFO closure, the two patients have more than 11 migraine attacks in the last year.
45 More interesting, the frequency of seizures in 3 patients with migraine after PFO
46 closure decreased significantly.
47
48
49
50
51
52
53
54

55 DISCUSSION

56
57
58
59
60

1
2
3 This is the first study to evaluate the relationship between migraine and right-to-left
4 shunt in a large number of patients with epilepsy. Our main findings were as follows:
5
6 1) one third of the migraineurs have mild right-to-left shunt and one fifth of the
7 migraineurs have moderate-to-large right-to-left shunt; 2) patients with mild
8 right-to-left shunt did not have a higher prevalence of migraine than those without
9 right-to-left shunt; 3) moderate-to-large right-to-left shunt was associated with
10 migraine in patients with epilepsy and 4) right-to-left shunt and female were factors
11 predicting migraine prevalence in patients with epilepsy.
12
13
14
15
16
17
18
19

20
21 Migraine in patients without epilepsy has been proved to be associated with CSD
22 and activation of the trigeminovascular system and its constituent neuropeptides.²² In
23 addition, recent studies also suggested the cortical excitatory/inhibitory imbalance due
24 to neuronal and glial ion channels renders patients more vulnerable to an headache
25 attack.²² Migraine in patients with epilepsy is not only associated with the
26 aforementioned mechanisms, but also is usually considered to be associated with
27 abnormal neuronal excitability induced by genetic variants.⁵⁻⁹ However, the high
28 prevalence of migraine in patients with epilepsy cannot be fully explained by genetic
29 variants. In the past 2 decades, right-to-left shunt have been found to be associated
30 with migraine in patients without epilepsy. Our major hypothesis was that right-to-left
31 shunt may also be one of the pathophysiological mechanisms of migraine in patients
32 with epilepsy. The results showed that mild right-to-left shunt was not associated with
33 migraine in patients with epilepsy. Almost one fifth of migraine were correlated with
34 moderate-to-large right-to-left shunt, which could be an underlying cause of migraine
35 in epilepsy. The mechanisms of the relationship between moderate-to-large
36 right-to-left shunt and migraine remains speculative. A previous study showed that
37 larger right-to-left shunt tend to trigger migraine attacks because of the increased
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 extent of the shunt.²³ Larger shunt allow harmful circulatory factors, such as
4 vasoactive substances and microemboli which are eliminated by lung, to bypass the
5 pulmonary filter and travel directly from the venous to the cerebral artery.
6
7 Right-to-left shunt and higher rates of Doppler-detected cerebral microemboli have
8
9 been reported to be associated.²⁴ In an animal experiment, air microemboli are able to
10
11 trigger CSD and migraine aura often with transient microvascular occlusion that is
12
13 insufficient to cause a permanent ischemic lesion.⁷ In humans, diagnostic microbubble
14
15 injection also induced attacks of migraine with aura.²⁵ Therefore, microemboli may be
16
17 a key role linking CSD, migraine, and moderate-to-large shunt.
18
19
20
21

22 Interestingly, CSD increases neuronal excitability and triggers ictiform activity in
23
24 neuronal tissues with partial impairment of inhibitory.⁹ CSD also triggers migraine
25
26 headache by activating neuronal Panx1 channels, which contributes to neuronal
27
28 hyperactivity in seizures.^{26,27} These findings may explain why migraine may have an
29
30 unfavourable effect on the prognosis of epilepsy.^{3,4} Therefore, moderate-to-large
31
32 right-to-left shunt may not only be an underlying cause of migraine but also an
33
34 adverse prognostic factor in patients with epilepsy. Whether moderate-to-large
35
36 right-to-left shunt is an adverse prognostic factors in epilepsy should also be
37
38 investigated.
39
40

41 The effect of PFO closure for migraine treatment still remains controversial.
42
43 Randomised controlled trials (RCTs) looking at the effect of PFO closure on migraine
44
45 were initially conducted. There are clinical trials showing that treatment for
46
47 right-to-left shunt did not increase responder rate defined as 50% reduction in
48
49 migraine attacks; however, it significantly reduced headache days.¹¹⁻¹⁴ Similarly to the
50
51 stroke trials, they had initial negative RCTs. With better patient selection and longer
52
53 follow-up, subsequent trials may show more cessation of migraine headache.²⁸ In our
54
55
56
57
58
59
60

1
2
3 cohort, we found that PFO closure fully controlled migraine in 2 of 4 cases. More
4 interesting, the frequency of seizures in 3 patients with migraine after surgery
5 decreased significantly. Although these cases need to be explained with caution, it is
6 worth investigating in the future whether PFO closure improve migraine attacks and
7 seizure outcomes. In addition, given the subjective nature of migraines and their
8 vulnerability to bias and the placebo effect, perhaps a large, well-designed sham
9 controlled trial with modern devices is required. If treatment for right-to-left shunt
10 have been shown to be definitely effective, right-to-left shunt should be screened in
11 patients with epilepsy and with migraine.
12
13
14
15
16
17
18
19
20
21

22 This study has some limitations. First, transoesophageal echocardiography (TEE) is
23 a gold standard diagnostic tool with a sensitivity and specificity of 80% to 100% for
24 the detection of a right-to-left shunt.^{19 20} The contrast TTE used by us has a lower
25 sensitivity than TEE.¹⁹ However, harmonic imaging improves sensitivity for the
26 detection of right-to-left shunt, ranging from 66% to 100%.^{19 20 29 30} In addition, TTE
27 is not inferior to TEE in the assessment of large shunt because TEE may miss large
28 shunt detected by TTE.³⁰ In our study, moderate-to-large right-to-left shunt are more
29 likely to be associated with migraine; therefore, TTE may not be an inferior choice to
30 TEE. Second, the population may be biased because a few patients did not complete
31 TTE. However, there were no differences in demographic characteristics between
32 patients who did or did not refuse TTE and the conclusions of our study should not be
33 affected. Third, only Chinese people were recruited, and this limits the
34 generalizability of results.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 52 **CONCLUSIONS**

53
54 Moderate-to-large right-to-left shunt but not mild right-to-left shunt were associated
55
56
57
58
59
60

1
2
3 with migraine. On the basis of these results, patients with epilepsy and with migraine
4 should be screened for a right-to-left shunt if treatment for a right-to-left shunt has
5 been shown to be effective in migraine. Whether moderate-to-large right-to-left shunt
6 is an adverse prognostic factor in epilepsy should be also investigated.
7
8
9
10

11
12
13 **Acknowledgements** No patient advisers were involved in the study. We thank Dr. Qi
14 Si for her help.
15
16
17
18
19

20 **Contributors** Lei Chen and Mingming Ning conceived and designed the work. Lin
21 Zhang and Xi Zhu were involved in data collection, data analysis and interpretation.
22 Lin Zhang drafted the manuscript. Lei Chen involved in critical revision of the article
23 and final approval of the version to be published. Xiangmiao Qiu, Xiangmiao Qiu,
24 Shixu He, Anjiao Peng, Wanlin Lai, Yajiao Li, Yucheng Chen, and Hui Wang were
25 involved in the data collection and final approval of the version to be published. All
26 authors have agreed to be accountable for all aspects of the work.
27
28
29
30
31
32
33
34
35
36

37 **Funding** Funding for this study was provided by China Association Against Epilepsy
38 (No.2016005).
39
40
41
42
43

44 **Competing interests** None declared.
45
46
47

48 **Patient consent** Obtained.
49
50
51

52 **Ethics approval** The protocol was approved by the Ethics Committee of the West
53 China Hospital of Sichuan University.
54
55
56
57
58
59
60

Data sharing statement No additional data available.

REFERENCES

1. Keezer MR, Bauer PR, Ferrari MD, *et al.* The comorbid relationship between migraine and epilepsy: a systematic review and meta-analysis. *Eur J Neurol* 2015;22:1038-47.
2. Le H, Tfelt-Hansen P, Russell MB, *et al.* Co-morbidity of migraine with somatic disease in a large population-based study. *Cephalalgia* 2011;31:43-64.
3. Dragoumi P, Tzetzis O, Vargiami E, *et al.* Clinical course and seizure outcome of idiopathic childhood epilepsy: determinants of early and long-term prognosis. *BMC Neurol* 2013;13:206.
4. Velioglu SK, Boz C, Ozmenoglu M. The impact of migraine on epilepsy: a prospective prognosis study. *Cephalalgia* 2005;25:528-35.
5. Finocchi C, Del Sette M. Migraine with aura and patent foramen ovale: myth or reality? *Neurol Sci* 2015;36 Suppl 1:61-6.
6. Ludvigsson P, Hesdorffer D, Olafsson E, *et al.* Migraine with aura is a risk factor for unprovoked seizures in children. *Ann Neurol* 2006;59:210-3.
7. Nozari A, Dilekoz E, Sukhotinsky I, *et al.* Microemboli may link spreading depression, migraine aura, and patent foramen ovale. *Ann Neurol* 2010;67:221-9.
8. Winawer MR, Connors R. Evidence for a shared genetic susceptibility to migraine and epilepsy. *Epilepsia* 2013;54:288-95.

- 1
2
3
4 9. Eickhoff M, Kovac S, Shahabi P, *et al.* Spreading depression triggers ictiform
5 activity in partially disinhibited neuronal tissues. *Exp Neurol* 2014;253:1-15.
6
7
- 8
9 10. Wammes-van der Heijden EA, Tijssen CC, Egberts AC. Right-to-left shunt
10 and migraine: the strength of the relationship. *Cephalalgia* 2006;26:208-13.
11
12
- 13 11. Xing YQ, Guo YZ, Gao YS, *et al.* Effectiveness and Safety of Transcatheter
14 Patent Foramen Ovale Closure for Migraine (EASTFORM) Trial. *Sci Rep*
15 2016;6:39081.
16
17
- 18 12. Tobis JM, Charles A, Silberstein SD, *et al.* Percutaneous Closure of Patent
19 Foramen Ovale in Patients With Migraine: The PREMIUM Trial. *J Am Coll*
20 *Cardiol* 2017;70:2766-74.
21
22
- 23 13. Dowson A, Mullen MJ, Peatfield R, *et al.* Migraine Intervention With
24 STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind,
25 sham-controlled trial to evaluate the effectiveness of patent foramen ovale
26 closure with STARFlex septal repair implant to resolve refractory migraine
27 headache. *Circulation* 2008;117:1397-404.
28
29
- 30 14. Mattle HP, Evers S, Hildick-Smith D, *et al.* Percutaneous closure of patent
31 foramen ovale in migraine with aura, a randomized controlled trial. *Eur Heart*
32 *J* 2016;37:2029-36.
33
34
- 35 15. Kanwar SM, Noheria A, DeSimone CV, *et al.* Coincidental Impact of
36 Transcatheter Patent Foramen Ovale Closure on Migraine with and without
37 Aura - A Comprehensive Meta-Analysis. *Clin Trials Regul Sci Cardiol*
38 2016;15:7-13.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16. Shi YJ, Lv J, Han XT, *et al.* Migraine and percutaneous patent foramen ovale closure: a systematic review and meta-analysis. *BMC Cardiovasc Disord* 2017;17:203.
17. Fisher RS, Cross JH, French JA, *et al.* Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia* 2017;58:522-30.
18. Ettl DA. The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia* 2013;33:629-808.
19. Cotter PE, Martin PJ, Belham M. Improved sensitivity of transthoracic contrast echocardiography in the detection of right-to-left shunts. *J Am Soc Echocardiogr* 2010;23:578; author reply 78-9.
20. Ha JW, Shin MS, Kang S, *et al.* Enhanced detection of right-to-left shunt through patent foramen ovale by transthoracic contrast echocardiography using harmonic imaging. *Am J Cardiol* 2001;87:669-71.
21. Mas JL, Arquizan C, Lamy C, *et al.* Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. *N Engl J Med* 2001;345:1740-6.
22. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. *Annu Rev Physiol* 2013;75:365-91.
23. Tembl J, Lago A, Sevilla T, *et al.* Migraine, patent foramen ovale and migraine triggers. *J Headache Pain* 2007;8:7-12.

- 1
2
3
4 24. Rodriguez RA, Sinclair B, Weatherdon D, *et al.* Patent foramen ovale and
5
6 brain microembolization during scoliosis surgery in adolescents. *Spine (Phila*
7
8 *Pa 1976)* 2001;26:1719-21.
- 9
10
11 25. Dinia L, Roccatagliata L, Bonzano L, *et al.* Diffusion MRI during migraine
12
13 with aura attack associated with diagnostic microbubbles injection in subjects
14
15 with large PFO. *Headache* 2007;47:1455-6.
- 16
17
18 26. Karatas H, Erdener SE, Gursoy-Ozdemir Y, *et al.* Spreading depression
19
20 triggers headache by activating neuronal Panx1 channels. *Science*
21
22 2013;339:1092-5.
- 23
24
25 27. Santiago MF, Veliskova J, Patel NK, *et al.* Targeting pannexin1 improves
26
27 seizure outcome. *PLoS One* 2011;6:e25178.
- 28
29
30 28. Mojadidi MK, Zaman MO, Elgendy IY, *et al.* Cryptogenic Stroke and Patent
31
32 Foramen Ovale. *J Am Coll Cardiol* 2018;71:1035-43.
- 33
34
35 29. Clarke NR, Timperley J, Kelion AD, *et al.* Transthoracic echocardiography
36
37 using second harmonic imaging with Valsalva manoeuvre for the detection of
38
39 right to left shunts. *Eur J Echocardiogr* 2004;5:176-81.
- 40
41
42 30. Daniels C, Weytjens C, Cosyns B, *et al.* Second harmonic transthoracic
43
44 echocardiography: the new reference screening method for the detection of
45
46 patent foramen ovale. *Eur J Echocardiogr* 2004;5:449-52.
- 47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Migraine prevalence in different groups

Characteristics	Sample	Migraine (%)	P values
Gender			0.022
Male	169	29 (17.2)	
Female	170	49 (28.8)	
Current age, years			0.039
≤16	82	12 (11.0)	
>16	257	66 (25.7)	
Duration of epilepsy, years			0.001
≤10	235	42 (17.9)	
>10	104	36 (34.6)	
Onset age, years			0.421
≤16	183	39 (21.3)	
>16	156	39 (25.0)	
Seizure frequency in the last year			0.256
0-12	246	56 (22.8)	
13-52	33	11 (33.3)	
>52	28	7 (25.0)	
Unknown	32	4 (12.5)	
Number of AEDs			0.052
< or = 1	189	36 (19.0)	
> or = 2	150	42 (28.0)	
AEDs			0.299
Topiramate	66	20 (30.3)	
Valproate	126	29 (23.0)	

1				
2				
3	Levetiracetam	94	26 (27.7)	
4				
5	Oxcarbazepine	94	19 (20.2)	
6				
7	Lamotrigine	27	2 (7.4)	
8				
9	Carbamazepine	67	19 (28.4)	
10				
11	Phenytoin	20	4 (20.0)	
12				
13	Phenobarbital	12	2 (16.7)	
14				
15	Seizure types			0.319
16				
17	Focal onset seizure	68	10 (14.7)	
18				
19	Generalized onset seizure and focal	227	58 (25.6)	
20				
21	to bilateral tonic-clonic seizures			
22				
23	Undetermined	44	10 (22.7)	
24				
25	Familial epilepsy	11	5 (45.5)	0.135
26				
27	First-degree relatives	9	4 (44.4)	
28				
29	Second-degree relatives	2	1 (50.0)	
30				
31	No familial epilepsy	328	73 (22.3)	
32				
33	Right-to-left shunt			
34				
35	Grade 1	99	26 (26.3)	0.102
36				
37	Grade 2-3	41	16 (39.0)	0.003
38				
39	Grade 1-3	140	42 (29.6)	0.010
40				
41	Grade 0	199	36 (18.1)	
42				
43				
44				
45				

AEDs, antiepileptic drugs.

Table 2 High prevalence of migraine in patients with moderate to large right-to-left shunt

Characteristics	Right-to-left shunt			P
	Grade 2-3 (n=41)	Grade 1 (n=99)	Grade 0 (n=199)	
Male, n (%)	17 (41.5)	52 (52.5)	100 (50.3)	0.413
Age, years	26.9 ± 11.7	27.6 ± 13.7	26.4 ± 13.2	0.769
Onset age, years	19.3 ± 11.2	17.9 ± 12.4	17.8 ± 12.3	0.779
Duration, years	8.1 ± 8.9	9.7 ± 9.6	8.7 ± 9.1	0.580
Familial epilepsy, n (%)	2	2	7	0.648
Education, n (%)				0.772
0-6, years	13 (31.7)	24 (24.2)	52 (26.1)	
7-12, years	20 (48.8)	47 (47.5)	104 (52.3)	
≥13, years	8 (19.5)	28 (28.3)	43 (21.6)	
Seizure types, n (%)				0.085
Focal onset	7 (17.1)	22 (22.2)	39 (19.6)	
Generalized onset seizure and focal to bilateral tonic-clonic seizures	32 (78.0)	69 (69.7)	126 (63.3)	
Undetermined	2 (4.9)	8 (8.1)	34 (17.1)	
Seizure frequency in the last year, n (%)				0.284
0-12	27 (65.9)	71 (71.7)	148 (71.4)	
13-52	3 (7.3)	14 (14.1)	16 (8.0)	
>52	6 (14.6)	8 (8.1)	14 (7.0)	

Unknown	5 (12.2)	6 (6.1)	21 (14.1)	
Number of used AEDs				0.139
< or = 1, n (%)	25 (61.0)	47 (47.5)	117 (58.8)	
> or = 2, n (%)	16 (39.0)	52 (52.5)	82 (41.2)	
AEDs				0.735
Topiramate	10	21	35	
Valproate	8	45	74	
Levetiracetam	15	31	48	
Oxcarbazepine	12	34	48	
Lamotrigine	4	8	15	
Carbamazepine	8	28	31	
Phenytoin	1	6	13	
Phenobarbital	1	4	7	
Migraine, n (%)	16 (39.0)	26 (26.3)	36 (18.1)	0.010 ^a

The continuous data are presented as mean \pm standard deviation.

^a Bonferroni correction show statistical differences in grade 2-3 versus grade 0.

AEDs, antiepileptic drugs.

Table 3 Logistic regression analysis for migraine predictors

Characteristics	Odds ratio	95% confidence interval		P
		Lower	Upper	
Male	0.518	0.302	0.891	0.017
Current age, years	0.978	0.956	1.001	0.057
Right-to-left shunt	2.200	1.274	3.797	0.005
Duration of epilepsy, years	0.974	0.945	1.004	0.085
Familial epilepsy	2.828	0.765	10.453	0.119
Number of antiepileptic drugs > 1	1.354	0.784	2.340	0.277

Figure legends

Figure 1. The flow diagram




Figure 1. The flow diagram

136x127mm (300 x 300 DPI)

sTable 1 Characteristics of migraine

Characteristics	N=78
Criteria	
Duration >2 hours (<18 years) or > 4 hours (\geq 18 years) ¹	78
At least 5 (without aura) attacks or 2 (with aura) attacks ¹	78
Headache has at least two of the following four characteristics	78
Location	
Left or Right ¹	46
Bilateral	32
Intensity^{1,2}	
0-3	17
4-10 ¹	61
Pulsating quality ¹	53
Aggravation by or causing avoidance of routine physical activity ¹	51
During headache at least one of the following	
Nausea and/or vomiting ¹	62
Photophobia and Phonophobia ¹	55

¹Diagnostic criteria of International Classification of Headache Disorders–3

criteria (beta)

²Visual analogue scale scores

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5,6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5,6
Bias	9	Describe any efforts to address potential sources of bias	6,11
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6,7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7,8
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	7
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7,8
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7,8
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9,10,11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.